return equiti ttm
friday juli market open report second quarter
financi result exhibit slightli beat expect top
bottom line rais ep growth guidanc
due strong sale key franchis continu benefit tax reform
share pull back significantli past month due rova-
triniti failur concern humira biosimilar competit eu
revenu quarter billion line billion estim beat
consensu billion world-wide humira revenu billion slightli higher
estim billion consensu billion imbruvica revenu
record million estim million consensu
million hcv franchis sale million estim million
consensu million bottom line non-gaap ep estim
consensu varianc analysi expect consensu
actual result summar exhibit manag issu updat guidanc
non-gaap ep new non-gaap ep estim
also slightli lower ep estim
due slightli lower price increas humira match inflat
unit state potenti backlash humira price increas practic
note two phase studi number phase ii studi rova-t monotherapi
combin on-going rova-t far dead reach agreement
competitor includ market perform
stave biosimilar entri humira key patent portfolio remain
unscath date lower humira price increas model match
inflat project top- bottom-lin compound-annual-growth-rate
respect affect fair valu
help drive growth share opinion orilissa
recent approv treatment endometriosis-associ pain launch schedul
august supplementari new drug applic snda heavi menstrual bleed
associ uterin fibroid track nda upadacitinib rheumatoid
arthriti ra schedul submiss fourth quarter follow potenti
approv second half expect approv risankizumab psoriasi
consid low risk event number snda submiss venclexta
imbruvica also plan near futur manag expect launch
new product label expans humira biosimilar competit begin unit
state believ help diversifi product mix sustain growth follow loss
exclus compani flagship product
biopharmaceut compani major busi franchis autoimmun oncolog virolog
area base north chicago illinoi
commerci launch multipl new franchis well label extens
number late-stag pipelin catalyst expect next month
second-quart slight full-year ep rais pipelin catalyst
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
second-quart net revenu billion repres growth year-ago period growth
sequenti top three product humira sale grew year-over-year imbruvica grew year-over-
year hcv franchis sale increas quarter-over-quart bolster strong mavyret uptak
domin humira franchis persever despit new competit price pressur sale maintain double-digit year-
over-year growth consecut quarter second quarter exhibit world-wide year-over-
year humira growth attribut increas unit state price increas
increas intern exhibit account adjust sale quarter imbruvica
revenu grew quarter-over-quart includ increas sale increas intern
profit share expect imbruvica continu domin second-lin chronic lymphocyt leukemia cll set
well continu expans frontlin cll margin zone lymphoma mzl chronic graft-versus-host diseas gvhd
hcv franchis sale show continu momentum strong first quarter total million mavyret
alreadi reach hcv market share highest script volum among singular hcv drug
continu forecast peak market share mavyret franchis reach equilibrium gilead
updat estim follow lower full year revenu estim billion
billion due decreas humira sale estim billion billion previous believ
price pressur may remain humira thu lower annual price increas match inflat
also slightli increas sale estim imbruvica billion billion reflect strong
imbruvica sale experienc quarter-over-quart growth new non-gaap ep estim
previous near top end guidanc also lower ep estim
previous due lower price increas humira manag comment compani continu aim
oper margin
base follow methodolog maintain fair valu estim share
updat pipelin project view exhibit continu trade signific discount peer
large-cap biotech pharma compani exhibit maintain averag price-to-earnings multipl comp group
valuat purpos take averag time non-gaap ep estim time estim
time estim multipl chosen percentil compar biotech
pharmaceut multipl given year use formula arriv fair valu estim share
compound-annual-growth-rate describ continu believ gradual share could garner higher-than-averag
look numer near-term product launch multibillion-dollar potenti well label expans within
key franchis throughout next month drive top- bottom-lin growth continu support
growth potenti neg humira headlin continu believ pipelin numer
upcom de-risk catalyst across variou therapeut field off-set impact eu humira biosimilar entri
 biosimilar entri
regulatori file upadacitinib ra expect fourth quarter follow potenti approv
current forecast upadacitinib bring peak sale across numer indic billion billion
attribut sale ra second quarter report top-lin result select-
earli fifth final registr trial phase program investig inhibitor
upadacitinib ra upadacitinib appear demonstr highest potenc among market jak
inhibitor xeljanz olumi market
perform initi data filgotinib gilead galapago glpg also appear slightli weaker
upadacitinib though data still rel earli howev safeti remain question upadacitinib
jak inhibitor class whole particularli relat sever cardiovascular cv risk includ venou
thromboembol event vte note recent approv olumi suffer numer imbal
vte event across placebo-control portion phase program ultim result approv
lower two propos dose well limit label popul black box warn cite
upadacitinib comparator-tr patient believ data begin lift prior concern
regard associ jak inhibit cv risk combin demonstr efficaci across spectrum
moderate-to-sever ra indic believ upadacitinib pois becom prefer agent among
orilissa launch next month treatment endometriosis-associ pain snda treatment
heavi menstrual bleed hmb associ uterin fibroid uf expect follow potenti
approv project orilissa reach blockbust statu bring sale billion across
indic partnership develop orilissa
elagolix first-in-class small-molecul gonadotropin-releas hormon receptor gnrh antagonist safer
effect treatment symptom associ endometriosi uf orilissa garner first approv
earlier month treatment endometriosis-associ pain schedul launch unit state
end august addit compani pursu hmb-associ uf second indic
orilissa compani announc posit top-lin result duplic phase trial indic earlier
year plan submit snda potenti approv follow guid
estim orilissa sale billion uf endometriosi indic believ valu
asset probabl underappreci continu project billion peak sale indic even
moder penetr
risankizumab continu schedul like approv launch moder sever psoriasi
follow approv indic next five seven year second quarter compani
submit biolog licens applic bla risankizumab fda european ema treatment
patient moder sever psoriasi base four phase pivot trial show impress
durabl skin clearanc believ risankizumab well-posit approv first indic
addit indic evalu next five seven year estim sale risankizumab reach
billion
imbruvica continu cornerston hematolog oncolog franchis eight approv
indic sever late-stag develop quarter compani report posit result
two imbruvica combin studi treatment frontlin chronic lymphocyt leukemia cll
phase illumin studi imbruvica gazyva significantli improv progression-fre surviv compar
gazyva chlorambucil current standard care phase ii captiv trial imbruvica venclexta led
minim residu diseas neg patient togeth studi repres addit opportun
penetr frontlin cll market note frontlin mainten set cll compris
largest treatment popul substanti longer treatment durat deeper penetr market
continu fuel imbruvica growth maintain market-lead posit late-stag monotherapi
combin studi imbruvica also on-going frontlin pancreat cancer frontlin mantl cell lymphoma
second-lin follicular lymphoma third-lin multipl myeloma could see approv throughout next
three four year note earlier juli partner johnson johnson announc
phase studi imbruvica frontlin non-gcb dlbcl fail meet primari endpoint improv
event-fre surviv ef part billion global peak sale estim imbruvica
model billion peak sale attribut dlbcl launch took dlbcl revenu
model affect ep estim valuat share main sourc revenu
imbruvica continu come chronic lymphoblast leukemia cll frontlin market share gain
entrench well durat therapi major driver growth
numer label expans venclexta beyond second quarter venclexta gain
second label indic treatment patient relapsed/refractori r/r cll combin
rituxan strong result venclexta gazyva frontlin cll present fourth quarter approv
indic expect snda venclexta combin hypomethyl agent low-
dose cytarabin frontlin acut myeloid leukemia aml submit juli breakthrough therapi
design anticip approv indic earli pivot studi also on-going number
addit non-hodgkin lymphoma type includ follicular lymphoma dlbcl waldenstrom
macroglobulinemia across indic compani project venclexta see five label expans
venclexta also evalu treatment myelodysplast syndrom could support
maintain outperform rate fair valu estim assum price-to-earnings multipl among
pharma biotech peer base model chang project top- bottom-lin compound-annual-growth-rate
respect beyond humira revenu start
declin continu project top- bottom-lin compound-annual-growth-rate respect note project
includ current market product late stage pipelin candid believ current earlier stage asset
start contribut growth beyond share remain under-valued opinion stock trade
discount pharma biotech peer despit fact current repres one highest growth rate
pharma biotech peer group fair valu estim put among top term price-to-earnings multipl
believ growth prospect well strong pipelin deserv premium
risk outperform rate includ earlier-than-project biosimilar entri humira failur
market product fulfil expect failur key pipelin program commerci success polit
risk busi develop risk
humira hcv imbruvica total sg acquir in-process research expense- total oper interest expens net foreign exchang incom expens pre-tax incom tax net non- net intang asset separ mileston acquir acquisit relat intang asset impairment- tax reform repatri tax- impact relat tax law change- tax audit settlement- legal reserves- restructuring- chang fair valu conting transact charit other- non- dividend per common weight averag share outstand compani report william blair inc incom estimatespreadvarianceq/q growthy/i growthcon estimate humira oper net compani report william blair estimatescurr quarterexhibit inc current quarter varianc analysi dollar billion except ep william blair
compani reportsexhibit inc humira world-wide y/i y/i growth compani report william blair estimatesexhibit inc humira y/i growth y/i growtheu y/i growthww y/i record record record record exclud top record abbvi william blair co estimatesexhibit inc estim product revenu william blair
biotechnolog consult last page report disclosur price factset william blair co inc exhibit import disclosur
